Summary & Overview
HCPCS J2778: Ranibizumab Injection, 0.1 mg
HCPCS Level II code J2778 denotes an injection of ranibizumab, 0.1 mg, an anti-VEGF medication administered via intravitreal injection to manage retinal diseases that threaten vision. Nationally, accurate coding for this drug matters for care continuity, billing consistency, and proper tracking of high-cost ophthalmic therapies.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical role, common sites of service, and the payer landscape relevant to coverage and claim adjudication. The publication summarizes benchmarking and reimbursement context where available, outlines common billing considerations tied to intravitreal injections, and highlights recent policy developments and coding guidance that affect access and prior authorization practices.
This summary is intended for clinicians, coding professionals, and revenue cycle staff seeking a national overview of HCPCS Level II code J2778, its clinical application, and the payer considerations that influence billing and coverage for ranibizumab intravitreal therapy.
Billing Code Overview
HCPCS Level II code J2778 represents an injectable formulation of ranibizumab, specified as 0.1 mg per dose. This medication is an anti-VEGF (vascular endothelial growth factor) agent used primarily for intravitreous injection to treat retinal vascular conditions that can cause vision loss.
Service Type: Injection (intravitreous administration)
Typical Site of Service: Outpatient ophthalmology clinic or ambulatory surgical center
Clinical & Coding Specifications
Clinical Context
A 72-year-old patient with age-related macular degeneration presents to the ophthalmology clinic with progressive central vision loss and metamorphopsia in the right eye. The retina specialist performs a pre-injection assessment including visual acuity, intraocular pressure, slit-lamp exam, and dilated fundus exam. Optical coherence tomography (OCT) confirms subretinal fluid and choroidal neovascularization consistent with neovascular (wet) AMD. After informed consent, the provider prepares a sterile field in an ambulatory procedure room or ophthalmology clinic procedure suite and administers an intravitreal injection of J2778 (ranibizumab, 0.1 mg) into the vitreous cavity. The visit includes medication administration, brief observation for immediate adverse events, documentation of laterality using modifier LT or RT as applicable, and scheduling of follow-up for repeat injections or monitoring. Typical site of service is an outpatient ophthalmology clinic or hospital outpatient department (ambulatory procedure area). Typical providers are vitreoretinal specialists, ophthalmologists, or retina-trained optometrists working under the supervising physician.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
LT | Left side |